1. Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy: a systematic review and meta-analysis

   • Ádám Széles
   • Tamás Fazekas
   • Tibor Szarvas

   Review Open access 16 November 2022 Pages: 1061 - 1073

   

2. Local immunotherapy with the RNA-based immune stimulator CV8102 induces substantial anti-tumor responses and enhances checkpoint inhibitor activity

   • Johannes Lutz
   • Michael Meister
   • Regina Heidenreich

   Research Open access 02 November 2022 Pages: 1075 - 1087

   

3. Inhibition of the CCR6-CCL20 axis prevents regulatory T cell recruitment and sensitizes head and neck squamous cell carcinoma to radiation therapy

   • Cleopatra Rutihinda
   • Ryma Haroun
   • Ayman J. Oweida

   Research 03 November 2022 Pages: 1089 - 1102

   

4. Immunotherapy for lung cancer combining the oligodeoxynucleotides of TLR9 agonist and TGF-β2 inhibitor

   • Yunpeng Yao
   • Jianhua Li
   • Liying Wang

   Research 03 November 2022 Pages: 1103 - 1120

   

5. Transcriptomic characterization and construction of M2 macrophage-related prognostic and immunotherapeutic signature in ovarian metastasis of gastric cancer

   • Jianpeng Gao
   • Zhenxiong Zhao
   • Hongda Pan

   Research 07 November 2022 Pages: 1121 - 1138

   

6. Egr2 and 3 maintain anti-tumour responses of exhausted tumour infiltrating CD8 + T cells

   • Alistair L. J. Symonds
   • Tizong Miao
   • Ping Wang

   Research Open access 07 November 2022 Pages: 1139 - 1151

   

7. Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated inhibition in cancer immunotherapy

   • Katharina H. Susek
   • Ysabel A. Schwietzer
   • Evren Alici

   Research Open access 10 November 2022 Pages: 1153 - 1167

   

8. Combined pembrolizumab and bevacizumab therapy effectively inhibits non-small-cell lung cancer growth and prevents postoperative recurrence and metastasis in humanized mouse model

   • Tianyun Qiao
   • Jinbo Zhao
   • Yong Han

   Research Open access 10 November 2022 Pages: 1169 - 1181

   

9. Correction to: Combined pembrolizumab and bevacizumab therapy effectively inhibits non-small-cell lung cancer growth and prevents postoperative recurrence and metastasis in humanized mouse model

   • Tianyun Qiao
   • Jinbo Zhao
   • Yong Han

   Correction Open access 26 December 2022 Pages: 1183 - 1183

10. Novel ocular immunotherapy induces tumor regression in an equine model of ocular surface squamous neoplasia

    • Kathryn L. Wotman
    • Lyndah Chow
    • Steven Dow

    Research 11 November 2022 Pages: 1185 - 1198

    

11. Somatic ARID1A mutation stratifies patients with gastric cancer to PD-1 blockade and adjuvant chemotherapy

    • Yun Gu
    • Puran Zhang
    • Weijuan Zhang

    Research Open access 12 November 2022 Pages: 1199 - 1208

    

12. Expansions of tumor-reactive Vdelta1 gamma-delta T cells in newly diagnosed patients with chronic myeloid leukemia

    • Andrea Knight
    • Martin Piskacek
    • Jiri Mayer

    Research Open access 14 November 2022 Pages: 1209 - 1224

    

13. Nonlinear association between body mass index and overall survival in advanced NSCLC patients treated with immune checkpoint blockade

    • Aditya Jain
    • Shijia Zhang
    • Amit A. Kulkarni

    Research 16 November 2022 Pages: 1225 - 1232

    

14. Expanded natural killer cells potentiate the antimyeloma activity of daratumumab, lenalidomide, and dexamethasone in a myeloma xenograft model

    • Jaya Lakshmi Thangaraj
    • Sung-Hoon Jung
    • Je-Jung Lee

    Research Open access 16 November 2022 Pages: 1233 - 1246

    

15. Improved MAIT cell functions following fecal microbiota transplantation for metastatic renal cell carcinoma

    • Marina Ninkov
    • Crystal L. Schmerk
    • S. M. Mansour Haeryfar

    Research 18 November 2022 Pages: 1247 - 1260

    

16. Identification of TCR rearrangements specific for genetic alterations in EGFR-mutated non-small cell lung cancer: results from the ADJUVANT-CTONG1104 trial

    • Cunte Chen
    • Siyang Maggie Liu
    • Yangqiu Li

    Research 24 November 2022 Pages: 1261 - 1272

    

17. Senescence-associated secretory proteins induced in lung adenocarcinoma by extended treatment with dexamethasone enhance migration and activation of lymphocytes

    • Prahlad Parajuli
    • Rayna Rosati
    • Manohar Ratnam

    Research 25 November 2022 Pages: 1273 - 1284

    

18. Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer

    • Yoshinori Kajiwara
    • Hiroshi Tazawa
    • Toshiyoshi Fujiwara

    Research 27 November 2022 Pages: 1285 - 1300

    

19. Expansion of KRAS hotspot mutations reactive T cells from human pancreatic tumors using autologous T cells as the antigen-presenting cells

    • Sizhen Wang
    • Xiaohui Zhang
    • Xinbo Wang

    Research 27 November 2022 Pages: 1301 - 1313

    

20. STAT3 promotes differentiation of monocytes to MDSCs via CD39/CD73-adenosine signal pathway in oral squamous cell carcinoma

    • Hao Cui
    • Zhou Lan
    • Guang-Tao Yu

    Research 27 November 2022 Pages: 1315 - 1326

    

21. Brief report: STING expressed in tumor and non-tumor compartments has distinct roles in regulating anti-tumor immunity

    • Jennie C. Kim
    • Xian Liu
    • Jackson G. Egen

    Brief Report Open access 17 November 2022 Pages: 1327 - 1335

    

22. Correction to: Let‑7d inhibits intratumoral macrophage M2 polarization and subsequent tumor angiogenesis by targeting IL‑13 and IL‑10

    • Boxing Su
    • Haibo Han
    • Liqun Zhou

    Correction 14 February 2023 Pages: 1337 - 1338

    

23. Correction to: TIGIT blockade enhances tumor response to radiotherapy via a CD103 + dendritic cell-dependent mechanism

    • Kaikai Zhao
    • Liyang Jiang
    • Xiangjiao Meng

    Correction Open access 21 February 2023 Pages: 1339 - 1341